Skip to main content
SpringerLink
Log in

Die Rolle der Rezeptortyrosinkinasen in der Angiogenese

Funktionen und therapeutische Implikationen

  • Weiter- und Fortbildung Rezeptortyrosinkinasen
  • Published:
Der Hautarzt Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Beliveau R, Gingras D, Kruger EA et al.(2002) The antiangiogenic Agent Neovastat (AE-941) inhibits vascular endothelial growth factormediated biological effects. Clin Cancer Res 8:1242–1250

    PubMed  CAS  Google Scholar 

  2. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365

    Article  PubMed  CAS  Google Scholar 

  3. Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404–407

    Article  PubMed  CAS  Google Scholar 

  4. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE (2000) Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60:5117–5124

    PubMed  CAS  Google Scholar 

  5. Cheng N, Brantley D, Chen J (2002) The ephrins and Eph receptors in angogenesis. Cytokine Growth Factor Rev 13:75–85

    Article  PubMed  CAS  Google Scholar 

  6. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25

    Article  PubMed  CAS  Google Scholar 

  7. Flanagan JG, Vanderhaeghen P (1998) The ephrins and Eph receptors in neural development. Annu Rev Neurosci 21:309–345

    Article  PubMed  CAS  Google Scholar 

  8. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat 1:27–31

    Article  CAS  Google Scholar 

  9. Frisén J, Holmberg J, Barbacid M (1999) Ephrins and their Eph receptors: multitalented directors of embryonic development. EMBO J 18:5159–5165

    Article  PubMed Central  PubMed  Google Scholar 

  10. Gale NW, Holland SJ, Valenzuela DM et al.(1996) Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17:9–19

    Article  PubMed  CAS  Google Scholar 

  11. Gale NW, Yancopoulos GD (1999) Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13:1055–1066

    Article  PubMed  CAS  Google Scholar 

  12. Hess AR, Seftor EA, Gardner LM et al. (2001) Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 61:3250–3255

    PubMed  CAS  Google Scholar 

  13. Kong HL, Hecht D, Song W et al.(1998) Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9:823–833

    Article  PubMed  CAS  Google Scholar 

  14. Laird AD, Vajkoczy P, Shawver LK et al. (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152–4160

    PubMed  CAS  Google Scholar 

  15. Marmé D (2001) Tumorangiogenese: Neue Ansätze zur Krebstherapie. Onkologie 24 [Suppl 1]:1–5

    PubMed  Google Scholar 

  16. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579

    Article  PubMed  CAS  Google Scholar 

  17. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22

    PubMed  CAS  Google Scholar 

  18. Papetti M, Herman IM (2002) Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282:C947–C970

    Article  PubMed  CAS  Google Scholar 

  19. Rosen LS, Mulay M, Mayers A et al.(1999) Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 18:161a

    Google Scholar 

  20. Rosen LS (2002) Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9:36–44

    PubMed  Google Scholar 

  21. Saleh M, Stacker SA, Wilks AF (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393–401

    PubMed  CAS  Google Scholar 

  22. Siemeister G, Martiny-Baron G, Marme D (1998) The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev 17:241–248

    Article  PubMed  CAS  Google Scholar 

  23. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3:1222–1227

    Article  PubMed  CAS  Google Scholar 

  24. Straume O, Akslen LA (2002) Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol 160:1009–1019

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  25. Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702–6704

    PubMed  CAS  Google Scholar 

  26. Vogt T, Stolz W, Welsh J et al. (1998) Overexpression of of LERK-5/EPLG5 mRNA: A novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 4:791–797

    PubMed  CAS  Google Scholar 

  27. Wood J, Bold G, Buchdunger E et al. (2000) PTK787/ZK222584,a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosin kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie, Universität Regensburg, Franz-Josef-Strauß-Allee 11, 93042, Regensburg, Deutschland

    S. Meyer, C. Hafner &  Thomas Vogt

Authors
  1. S. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Hafner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Vogt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Vogt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meyer, S., Hafner, C. & Vogt, T. Die Rolle der Rezeptortyrosinkinasen in der Angiogenese. Hautarzt 53, 629–643 (2002). https://doi.org/10.1007/s00105-002-0425-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-002-0425-x

Search

Navigation